Lehigh Valley Health Network is a healthcare network based in the Allentown, Pennsylvania in the Lehigh Valley region of the state. The healthcare network serves eastern and northeastern Pennsylvania. Its flagship hospital is Lehigh Valley Hospital, located on Cedar Crest Boulevard in Allentown.
BACKGROUND:Mechanical thrombectomy is the standard of care for large vessel occlusion (LVO) stroke, yet most device trials focus on individual technologies rather than complete systems. OBJECTIVE:To evaluate the safety and efficacy of the Zoom Reperfusion System compared with performance goals derived from a meta-analysis of trials using established thrombectomy technologies. METHODS:Prospective, multicenter, non-randomized, investigational device exemption trial conducted across 26 United States centers from October 2021 to March 2024. Adults with anterior circulation LVO stroke within 8 hours of onset were treated using the Zoom System, which includes aspiration catheters ranging from 0.035″ to 0.071″, and a novel 0.088″ intracranial guide/aspiration catheter. The primary efficacy endpoint was successful reperfusion (modified Thrombolysis in Cerebral Infarction (mTICI) 2b-3) within three passes using Zoom-only components, adjudicated by an independent core laboratory. The primary safety endpoint was symptomatic intracranial hemorrhage (sICH). Secondary outcomes included final reperfusion, first-pass success, time to reperfusion, 90-day modified Rankin Scale (mRS), and mortality. RESULTS:Among 260 patients (median age 68 years; median National Institutes of Health Stroke Scale (NIHSS) 15), successful reperfusion within three passes was achieved in 83% (216/259; 95% CI: 78% to 89%), exceeding the performance goal (p<0.001). Final reperfusion was 92%, with 5.5% requiring rescue devices. First-pass mTICI 2b-3 success was 57%. Median puncture-to-reperfusion time was 19 min. At 90 days, 55% achieved mRS 0-2. The sICH rate was 1.9%, and 90-day mortality was 12.7%. CONCLUSIONS:The Zoom Reperfusion System demonstrated a safety and efficacy profile exceeding prespecified contemporary performance metrics with potential to significantly shorten reperfusion times and reduce the need for rescue therapy. TRIAL REGISTRATION NUMBER:ClinicalTrials.gov--Identifier:NCT04129125.
Middle meningeal artery embolization (MMAE) has emerged as a treatment for chronic subdural hematoma (cSDH), but comprehensive real-world safety data remain limited. We performed a multicenter retrospective analysis of 1781 consecutive patients undergoing MMAE for cSDH (2019–2025). The primary outcome was any procedure-related complication within 30 days. Inverse probability of treatment weighting (IPTW) assessed the association between technical success and complications, adjusting for demographic, clinical, and procedural confounders. Mean age was 72.8 ± 12.4 years; 68.1
Importance:The emergency medicine (EM) workforce is undergoing complex change, including a potential projected physician surplus, the volatile and evolving interests of medical students, and the continued high rates of burnout. Understanding the career intentions of graduating residents is critical to inform workforce planning. Objective:To examine the career plans, anticipated career durations, and key factors associated with the career decisions of graduating US EM residents. Design, Setting, and Participants:This cross-sectional survey study, which sampled graduating residents from all Accreditation Council for Graduate Medical Education-accredited categorical EM programs, was conducted after the 2023 American Board of Emergency Medicine In-Training Examination. Resident-level characteristics, including gender, race and ethnicity, educational debt, and burnout status, were examined. Data were obtained from June 20 to August 18, 2024, and analysis occurred from December 16, 2024, to August 12, 2025. Main Outcomes and Measures:Primary outcomes included immediate postresidency career plans, intended practice setting, anticipated years of clinical practice, and importance of 10 career decision factors. Results:Of 2782 eligible residents, 2711 (97.4%; 1394 men [51.4%]) responded to at least 1 survey item. Most respondents (1654 [61.0%]) reported educational debt exceeding $100 000; 1964 of 2239 respondents (72.4%) met criteria for burnout. Immediate career plans included community-based practice (852 [31.4%]), fellowship (631 [23.3%]), hybrid (community-based hospital affiliated with an academic medical center) (416 [15.3%]), and academic EM (161 [5.9%]). Most residents (1597 [58.9%]) intended to work in an urban setting, with 652 (24.1%) planning to work in a rural setting. The mean (SD) anticipated duration of clinical EM practice was 22.4 (8.3) years. The most important career decision factors were lifestyle (2135 of 2189 [97.5%]), geographic location (1930 of 2176 [88.7%]), professional fulfillment (1906 of 2173 [87.7%]), and salary expectations (1808 of 2183 [82.8%]). Female residents were more likely than male residents to report professional fulfillment and burnout as important factors and less likely to prioritize salary expectations. Residents with $200 000 or more in debt (1376 [50.7%]) were significantly more likely to cite salary as a major factor ($200 000-$299 000: odds ratio [OR], 2.01 [95% CI, 1.39-2.89]; $300 000-$399 000: OR, 2.31 [95% CI, 1.58-3.39]; ≥$400 000: OR, 1.58 [95% CI, 1.05-2.42]). Conclusions and Relevance:In this survey study of graduating EM residents in 2023, most respondents planned to practice clinical EM for 2 decades primarily in community or hybrid settings, with a minority of residents interested in rural practice. Career decisions are overarching and encompass career factors; lifestyle, location, professional fulfillment, and salary were the strongest career factors. Burnout, educational debt, and demographic characteristics were associated with career decisions. These findings have implications for workforce modeling, retention strategies, and policies to support the EM workforce.
Middle meningeal artery embolization (MMAE) plus surgical evacuation is increasingly used for chronic subdural hematoma (cSDH), but predictors of length of stay (LOS) and outcomes associated with early discharge remain unclear. We performed a multicenter MESH Registry study (2019–2024) of patients undergoing MMAE and surgical evacuation for symptomatic cSDH. Short-stay discharge was defined as LOS ≤4 days. Predictors were identified using multivariable logistic regression. The 90-day composite adverse event was defined as cSDH recurrence requiring intervention, reintervention (repeat MMAE or surgical evacuation), or 30-day all-cause readmission. Safety was assessed using adjusted logistic regression, generalized estimating equations (GEE), inverse probability of treatment weighting (IPTW), and multiple imputation by chained equations (MICE). Among 647 patients (mean age 72.6 years; 74.0
OBJECTIVE:The objective was to evaluate the trajectories of hematoma resolution and functional improvement after middle meningeal artery embolization (MMAE) for chronic subdural hematoma (cSDH), model the temporal pattern of cSDH resolution, and identify factors associated with favorable outcomes. METHODS:This real-world multicenter retrospective study included cSDH patients treated with MMAE at 24 centers between 2019 and 2024. Hematoma thickness was measured at baseline and at follow-up intervals (1-4 weeks, 1-3 months, 3-6 months, 6-12 months, and > 12 months after embolization). Resolution patterns were modeled using exponential decay functions. Modified Rankin Scale (mRS) scores assessed functional outcomes. Good functional outcome was defined as mRS score ≤ 2. Resolution patterns were modeled using exponential decay functions to estimate time to 50% and 80% reduction. Patients were categorized as complete resolution (≥ 99%) or by quartile of the remaining distribution (substantial [73%-98%], moderate [53%-73%], partial [27%-53%], minimal [< 27%]). The primary outcome was good functional status (mRS score ≤ 2). RESULTS:The authors analyzed a total of 1781 patients with 2295 cSDHs who underwent MMAE. The mean ± SD age was 72.8 ± 12.4 years and 68.1% of patients were male. The initial mean hematoma thickness was 15.31 ± 6.53 mm, decreasing to 5.24 ± 5.91 mm at final follow-up (mean reduction 64.3% ± 42.1%). Resolution followed an exponential decay pattern, with an estimated time to 50% reduction of 1.8 months and to 80% reduction of 8.9 months. Complete resolution occurred in 1031 of 2224 patients (46.4%) with complete follow-up. The median (IQR) mRS score improved from 1 (0-3) at baseline to 0 (0-2) at > 12 months. Good functional outcomes were more common in patients with complete versus minimal resolution (68.9% vs 35.0%, p < 0.001). Achieving ≥ 73% resolution within 90 days was associated with better outcomes (good outcome in 76.9% of those with ≥ 73% resolution vs 67.3% in those without, p < 0.001). Neurological deterioration was the strongest predictor of lack of good outcome (23.7% in patients with neurological deterioration vs 82.4% without, p < 0.001). CONCLUSIONS:After MMAE for cSDH, reduction in hematoma thickness follows a predictable exponential decay pattern. Greater extent (≥ 80%) and faster timing (within 90 days) of resolution are valuable prognostic indicators. Functional outcomes improve progressively through 6-12 months after the procedure. The relationship between resolution extent and functional outcomes provides quantitative benchmarks for evaluating treatment response.